ArticleFrontiers in oncology2020
Catalog of Lung Cancer Gene Mutations Among Chinese Patients.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Lung adenocarcinoma risk in an area with seasonal high PMFrontiers in public health · 2026Article
- HER2 mutations in pulmonary adenocarcinoma presenting with ground-glass nodules.World journal of surgical oncology · 2025Article
- Assessing mutation-clinical correlations and treatment outcomes in Vietnamese non-small cell lung cancer patients.Practical laboratory medicine · 2025Article
- Treatment of advanced lung adenocarcinoma with EGFR L833V/H835L compound mutations using furmonertinib: two case reports and literature review.Frontiers in medicine · 2025Article
- Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review.Ecancermedicalscience · 2024Article
- Correlation analysis of clinical, pathological, imaging and genetic features of ground-glass nodule featured lung adenocarcinomas between high-risk and non-high-risk individuals.European journal of medical research · 2023Article
- [Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
- A Fluorescent "Turn-On" Clutch Probe for Plasma Cell-Free DNA Identification from Lung Cancer Patients.Nanomaterials (Basel, Switzerland) · 2022Article
- Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report.Frontiers in oncology · 2022Article
- Prevalence of targeted therapy-related genetic variations in NSCLC and their relationship with clinicopathological characteristics.PloS one · 2022Article
- Females and Males Show Differences in Early-Stage Transcriptomic Biomarkers of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2021Article
- Assessment and Prognostic Value of Immediate Changes in Post-Ablation Intratumor Density Heterogeneity of Pulmonary TumorsFrontiers in oncology · 2021Article
- Genomic Mutations of Primary and Metastatic Lung Adenocarcinoma in Chinese Patients.Journal of oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.